Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sanofi : Drug Blocks Red Blood Cell Destruction In Late-Stage Study

06/11/2021 | 03:39am EDT


ę MT Newswires 2021
All news about SANOFI
04:49aANALYSIS : Sanofi's COVID-19 vaccine setback, drug pipeline cast long shadow
RE
08/04SANOFI : to acquire Translate Bio, advances deployment of mRNA technology across..
AQ
08/04PRESS RELEASE : BioNTech Completes Acquisition of Kite's Neoantigen TCR Cell The..
DJ
08/04SANOFI : UBS reaffirms its Buy rating
MD
08/03SANOFI : to acquire Translate Bio; advances deployment of mRNA technology across..
PU
08/03S&P 500 closes at record high as Apple, healthcare stocks help shrug off Delt..
RE
08/03Global markets live: Sanofi, Alphabet, BMW, Ford, Tencent...
08/03Sanofi bets on mRNA vaccines beyond COVID in $3.2 billion Translate Bio deal
RE
08/03Today on Wall Street: Corporate profits rise by a level not seen since 2009
08/03SECTOR UPDATE : Health Care Stocks Flat To Higher Pre-Bell Tuesday
MT
More news
Financials
Sales 2021 37 031 M 43 836 M 43 836 M
Net income 2021 6 060 M 7 173 M 7 173 M
Net Debt 2021 7 345 M 8 694 M 8 694 M
P/E ratio 2021 17,5x
Yield 2021 3,89%
Capitalization 106 B 126 B 126 B
EV / Sales 2021 3,06x
EV / Sales 2022 2,80x
Nbr of Employees 99 412
Free-Float 88,4%
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 84,50 €
Average target price 104,06 €
Spread / Average Target 23,1%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Chairman
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI7.37%125 533
JOHNSON & JOHNSON10.15%459 079
ROCHE HOLDING AG14.16%340 492
PFIZER, INC.22.77%255 703
ELI LILLY AND COMPANY55.45%232 701
NOVARTIS AG-0.20%224 638